EU Industry Finds Glaring Gaps In Health Data Access Proposal
Executive Summary
Protection of IP and trade secrets and the need for clarity around issues such as the rules on access to data and the sharing of clinical trial data are seen as key issues in the European Commission’s plans for a European Health Data Space.
You may also be interested in...
EU Health Data Law Would Make It ‘Easy’ To Scrape Competitors’ Databases, Trade Body Warns
Intellectual property conflicts, vague terminology, and excessive health data transfer requirements are among the problems with the proposed European Health Data Space highlighted in a new position paper by DIGITALEUROPE.
EU Parliament Says Pharma IP & Trade Secrets Must Be Protected Under Health Data Space
The European Parliament has adopted changes to the proposed European Health Data Space that would protect the intellectual property of pharma companies, but trade body EFPIA says the rules should be made clearer and warned the proposed system could cause “bottlenecks”.
EU Health Data Access Proposal Should Not Include Opt-Out Model, Pharma Says
The European Commission is mulling the addition of an opt-out mechanism for patients under its European Health Data Space framework, but health and pharma industry stakeholders have warned that this could cause “scientific damage” and act as a barrier to research.